Payment overview · 2025
General Payments
$34.88
2 reported records · 2 companies
Healthcare provider profile · identity verified
Douglas A Walsh, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · BRADENTON, FL · NPI 1356347520
Verified facts
What the public records show
CMS Open Payments records show Douglas A Walsh, D.O. received $34.88 in general payments during 2025 across 2 reported records.
ARS Pharmaceuticals Operations, Inc. accounted for 51.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $17.94 | 51.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.94 | 48.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $34.88 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 187 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
187 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 421 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 320 | 107 |
| Lisinopril | Lisinopril | 304 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 272 | 72 |
| Alprazolam | Alprazolam | 270 | 55 |
| Losartan Potassium | Losartan Potassium | 242 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 71 |
| Gabapentin | Gabapentin | 230 | 62 |
| Metformin Hcl | Metformin Hcl | 202 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 60 |
| Ozempic | Semaglutide | 187 | 37 |
| Furosemide | Furosemide | 183 | 66 |
| Trazodone Hcl | Trazodone Hcl | 175 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 47 |
| Ezetimibe | Ezetimibe | 150 | 43 |
| Omeprazole | Omeprazole | 145 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 38 |
| Meloxicam | Meloxicam | 119 | 44 |
| Topiramate | Topiramate | 111 | 34 |
| Famotidine | Famotidine | 109 | 31 |
| Buspirone Hcl | Buspirone Hcl | 105 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 30 |
| Atenolol | Atenolol | 98 | 29 |
| Potassium Chloride | Potassium Chloride | 96 | 33 |
| Mirtazapine | Mirtazapine | 95 | 28 |
| Simvastatin | Simvastatin | 95 | 30 |
| Montelukast Sodium | Montelukast Sodium | 93 | 25 |
| Carvedilol | Carvedilol | 90 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 23 |
| Tramadol Hcl | Tramadol Hcl | 85 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 26 |
| Amoxicillin | Amoxicillin | 77 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 18 |
| Ibuprofen | Ibuprofen | 73 | 18 |
| Jardiance | Empagliflozin | 72 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 13 |
| Terazosin Hcl | Terazosin Hcl | 64 | 20 |
| Diazepam | Diazepam | 60 | suppressed |
| Baclofen | Baclofen | 59 | 17 |
| Sertraline Hcl | Sertraline Hcl | 57 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 12 |
| Lorazepam | Lorazepam | 54 | 15 |
| Nifedipine Er | Nifedipine | 53 | 15 |
| Ondansetron Odt | Ondansetron | 53 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 18 |
| Prednisone | Prednisone | 48 | 22 |
| Azithromycin | Azithromycin | 46 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 15 |
| Eliquis | Apixaban | 45 | 18 |
| Glipizide | Glipizide | 45 | 14 |
| Temazepam | Temazepam | 45 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 45 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 45 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 15 |
| Allopurinol | Allopurinol | 42 | 15 |
| Pregabalin | Pregabalin | 42 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 20 |
| Glipizide Er | Glipizide | 41 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | 11 |
| Metformin Hcl Er | Metformin Hcl | 38 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | suppressed |
| Mupirocin | Mupirocin | 34 | 18 |
| Nitroglycerin | Nitroglycerin | 34 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | 13 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 20 |
| Methylprednisolone | Methylprednisolone | 31 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 15 |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 15 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Epinephrine | Epinephrine | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34.88 · 2 records | ARS Pharmaceuticals Operations, Inc. | NEFFY, Ozempic, Rybelsus | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error